Clinical Trial Update: Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of co-administering a commercially available vaccine with the GSK HPV vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Vaccination
• Papillomavirus Infection

Drugs mentioned

• GSK HPV vaccine (human papillomavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus, Papillomavirus Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2009-12-18